1-deoxynojirimycin has been researched along with valiolamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, I; Asano, N; Ikeda, K; Imahori, T; Kamiyama, O; Kato, A; Kuriyama, C; Okamoto, T; Sanae, F; Takahata, H | 1 |
| Brown, AN; Franco, EJ; Hanrahan, KC; Hill, DC; Karade, SS; Kolesnikov, A; MacKerell, AD; Mariuzza, RA; Rojas, AC; Treston, AM; Weber, DJ; Yu, W | 1 |
2 other study(ies) available for 1-deoxynojirimycin and valiolamine
| Article | Year |
|---|---|
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
Topics: Animals; Caco-2 Cells; Carbohydrate Conformation; Cells, Cultured; Dose-Response Relationship, Drug; Fibroblasts; Gaucher Disease; Glycogen; Glycoside Hydrolases; Hepatocytes; Humans; Imino Sugars; Lysosomes; Rats; Structure-Activity Relationship | 2008 |
Structure-Based Design of Potent Iminosugar Inhibitors of Endoplasmic Reticulum α-Glucosidase I with Anti-SARS-CoV-2 Activity.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Antiviral Agents; COVID-19; Endoplasmic Reticulum; Glycoproteins; Glycoside Hydrolase Inhibitors; Quantitative Structure-Activity Relationship; SARS-CoV-2 | 2023 |